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	 National Cancer Registry, 1980-1983 
G. Munoz & R. Sierra 
Legislation making cancer a notifiable disease 
was introduced in Costa Rica in 1976. At the same 
time, a National Tumour Registry was established, 
and collection of data commenced in March 1977. 
The aims of the National Tumour Registry, speci-
fied by legislation, were to collect data which would 
permit assessment of: 
( 1) the incidence and prevalence of cancer by 
anatomical site, sex, age, occupation and 
geographical area; 
(2) the distribution and quality of medical 
services provided to persons suffering from 
cancer; 
(3) all new cases of malignant cancer diag-
nosed within the national boundaries, and 
any other relevant problems. 
The Cancer Registry of Costa Rica obtains data 
on cancer cases from hospital records, death certi-
ficates, biopsies and autopsies. 
For every patient who leaves hospital with a 
diagnosis of malignant cancer, the following infor-
mation is given to the Cancer Registry: hospital and 
locality, clinical record number, name, sex and civil 
status, date and place of birth, age, occupation, 
habitual place of residence, diagnosis, basis of 
diagnosis, histological diagnosis and previous his-
tory of cancer. 
This information is collected on a standard 
form and used by the Registry to establish a patient 
index which permits the unequivocal identification 
of every person presenting with cancer. This index 
includes the patient's full name, identification num-
ber and registration number. 
Since 1980, the Registry has received a copy of 
all histological diagnoses of cancer from both 
public and private laboratories. 
The Pan American Health Organization has, 
since 1979, given technical support to the work of 
the Registry by arranging seminars in which Regis-
try personnel, as well as personnel from all hospi- 
tals in the area, can take part, and by sending 
consultants to visit and evaluate the Registry. 
In 1978, an Administrative Board was estab-
lished for the Registry, with the participation of 
pathologists, oncologists and statisticians of the 
Ministry of Health and of the Social Security 
System. 
Costa Rica is a small country (51 000 square 
kilometres) situated in Central America. The cen-
tral mountains divide the country into Caribbean 
and Pacific zones. The country is predominantly 
agricultural, the major crops being coffee, bananas 
and sugar cane. Cattle breeding is also an important 
industry. Costa Rica has one of the highest levels of 
education and health in Latin America — in 1983 
the infant mortality rate was 18.6 per 1000 live 
births, and average expectation of life at birth was 
73.7 years. Health services cover 98% of the popu-
lation. There is one doctor and seven nurses per 
1000 inhabitants, 29 hospitals and 184 clinics. 
Population 
The population at risk has been calculated from 
annual estimates of the population of Costa Rica 
(Centro Latino-Americano de Demografia, San 
Jose). 
AVERAGE ANNUAL POPULATION: 1980-1983 
Age Male Female 
0 36998 35262 
1-4 132757 127176 
5-9 145889 I40094 
10-14 143930 138331 
0-14 459574 440863 
Commentary 
The incidence rate for all diagnoses taken 
together is one of the highest in this volume, the rate 
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Costa Rica 1980 - 1983 MALE 
DIAGNOSTIC GROUP NUMBER OF CASES 
0 	 1-4 	 5-9 10-14 All 
REL. 
Crude 
FREQUENCY(%) 
Adj. 	 Group 0 1-4 
RATES 
5-9 
PER MILLION 
10-14 	 Crude Adj. Cum 
RV(%) 
TOTAL 18 103 83 78 282 100.8 100.0 100.0 121.6 194.0 142.2 135.5 153.4 154.7 2286 $0.7 
I. 	 GRUKAEMIAS 6 41 37 30 114 40.4 40.4 100.0 40.5 77.2 63.4 52.1 62.0 62.6 9.27 90.4 
Acute lymphocytic 4 33 29 20 06 30.3 30.4 75.4 27.0 62.1 49.7 34.7 46.6 47.5 696 89.5 
Other 	 lymphocytic 0 2 0 0 2 0.7 0.7 1.8 - 3.8 - - 1.1 1.2 IS 50.0 
Acute non-lymphocytic 0 5 4 7 16 5.7 5.6 14.0 - 9.4 6.9 12.2 8.7 6.7 133 93.0 
Chronic myeloid 1 1 0 1 3 1.1 1.0 2.6 6.6 1.9 - 1.7 1.6 1.6 23 100.0 
Other and unspecified 1 0 4 2 7 2.5 2.5 6.1 6.6 - 6.9 3.5 3.8 3.1 so 100.0 
II. 	 /AMP0011AS 2 31 22 15 70 24.8 24.6 100.0 13.5 58.4 37.7 26.1 38.1 38.8 566 91.4 
Hodgkin's disease 0 5 11 10 26 9.2 9.5 37.1 - 9.4 16.0 17.4 14.1 14.0 219 96.2 
Non-Hodgkin lymphoma 0 13 3 3 19 6.7 6.5 27.1 24.5 5.1 5.2 10.3 10.$ 150 64.2 
Burkitt's lymphoma 0 1 0 0 1 0.4 0.3 1.4 1.9 - - 0.5 0.6 8 100.0 
Unspecified lymphoma 0 7 7 1 15 5,3 5.2 21.4 - 13.2 12.0 1.7 0.2 8.5 121 93.3 
Hiatiocytosis X 0 3 L 1 5 1.6 1.7 7.1 - 5.6 1.7 1.7 2.7 2.0 40 00.0 
Other raticuloendothalial 2 2 0 0 4 1.4 1.3 5.7 13.5 3.6 - - 2.2 2.2 29 100.0 
III. BRAIN AND SPINAL 2 7 13 11 33 11.7 11.9 100.0 13.5 13.2 22.3 19.1 18.0 17.9 273 04.8 
Ependymoma 1 0 2 0 3 1.1 1.1 9.1 6.8 - 3.4 - 1.6 1.6 24 100.0 
Astrocytoam 1 2 3 2 6 2.8 2.0 24.2 6.8 3.8 5.1 3.5 4,4 4.4 65 100.0 
Medulloblastoma 0 2 5 '7 14 3.0 5.2 42.4 - 3.8 0.6 12.2 7.6 7.5 119 71.4 
Other glioma 0 3 3 1 7 2.5 2.5 21.2 - 5.6 5.1 1.7 3.6 3.9 57 05.7 
Other and unspecified * 0 0 0 1 1 0.4 0.4 3.0 - - - 1.7 0.5 0.5 9 100.0 
IV. 	 EIMPATNETIC N.B. 2 6 1 1 10 3.5 3.4 100.0 13.5 11.3 1.1 1.7 5.4 5.6 76 00.0 
Wauroblastoma 1. 6 1 1 9 3.2 3.1 90.0 6.6 11.3 1.7 1.7 4.9 5.1 69 77.0 
Other 1 0 0 0 1 0.4 0.3 10.0 6,5 - - - 0.5 0,5 / 100.0 
v. 	 1111r/NOBLASTONA 1 S 	 0 0 6 2.1 2.0 100.0 6.8 9.4 - - 3.3 3.4 44 100.0 
VI. 	 RIMINI . 2 3 1 1 7 2.5 7.4 100.0 13.5 5.6 1.7 1.7 3.4 3.9 53 71.4 
Niles' 	 tumour 2 2 1 1 6 7,1 2.1 05.7 13.5 3.6 1.7 1.7 3.3 3.1 46 66.7 
Renal carcinoma 0 0 6 0 0 - - - - - - - - - - 
Other 	 and unspecified 0 1 0 0 1 0.4 0.1 14.3 1.9 - 0.5 0,6 6 100.0 
VII. LIVER 0 0 1 4 5 1.8 1.9 100.0 - 1.7 6.9 2.7 2.6 43 60.0 
Hepatoblastoma 0 0 1 0 1 0.4 0.4 20.0 1.7 - 0.5 0.6 9 100.0 
Hepatic 	 carcinoma 0 0 0 4 4 1.4 1.5 00.0 - - 6.9 2.2 2.0 35 50.0 
Other 	 and unspecified 0 0 0 0 0 - - - - - - _ 
v2I/.130141 0 0 2 4 6 2.1 2.3 100.0 - 3.4 6.9 3.3 3.1 52 83.3 
Osteosarcoma 0 0 9 1 2 0.7 0.7 33.3 - - 1.7 1.1 1.1 1.1 17 50.0 
Chondrosarcoma 0 0 0 1 1 0.4 0.4 16.7 - 1.7 0.5 0.5 9 100.0 
eving's 	 sarcoma 0 0 0 2 2 0.7 0.6 33.3 - - 3.5 1.1 1.0 17 100.0 
Other 	 and unspecified 0 0 1 0 1 0.4 0.4 16.7 - - 1.7 - 0.5 0.6 9 100.0 
II. 	 SOFT TISSUR SARCOMAS 1 5 3 2 11 3.9 3.1 100.0 6.8 9.4 5.1 3.5 6.0 6.1 87 90.9 
Rhabdomyosarcoms 0 4 2 0 6 2.1 2.0 54.5 - 7.5 3.4 - 3.3 3.4 47 83.3 
ribrosarcoma 0 0 0 1 1 0.4 0.4 9.1 - - 1.7 0.5 0.5 9 100.0 
Other and unspecified 1 1 1 1 4 1.4 1.4 16.4 6.0 1.9 1.7 1.7 2.2 2,2 32 100.0 
I. 	 GONADAL 4 GERM CELL 1 4 1 0 6 7.1 2.0 100.0 6.8 7.5 1.7 - 3.3 3.4 45 83.3 
Non-gonadal 	 germ cell 0 9 1 0 2 0.7 0.7 33.3 - 1.9 1.7 - 1.1 1.1 16 100.0 
Gonadal 	 germ call 1 3 0 0 4 1.4 1.3 66.7 6.8 5.6 - 2.2 2.3 29 75.0 
Gonadal 	 carcinoma 0 0 0 0 0 - - - - - - - - 
Other 	 and unspecified 0 0 0 0 0 - - - - - - - - 
II. 	 EPITHELIAL NEOPLASMS 1 1 2 10 14 5.0 5.2 100.0 6.8 1.8 3.4 17.4 7.6 7.3 110 92.9 
Adrenocnrtical 	 carcinoma 0 0 0 0 0 - - 1 	 - - - - - - 
Thyroid carcinoma 0 0 1 0 1 0.4 0.4 7.1 - 1.7 - 0.5 0.6 9 100.0 
Hasopharyngeal 
	 carcinoma 0 0 0 7 7 2.5 2.7 50.0 - 12.2 3.6 3.5 61 100.0 
Melanoma 0 1 0 0 1 0.4 0.3 7.1 - 1.9 - 0.5 0.6 0 100.0 
Other carcinoma 1 0 1 3 s 1.8 1.2 35.7 6.0 1.7 5.2 2.7 2.6 41 80.0 
XII. OTHER 0 0 0 0 0 - - - - - - - _ - 
' 	 Specified as 	 malignant 0 0 0 1 1 0,4 0.4 100.0 1.7 0.5 0.5 9 100.0 
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Costa Rica 1980 - 1983 FEMALE 
DIAGNOSTIC GROUP NUMBER OF CASES 
0 	 1-4 	 5-9 10-14 All 
REL. 
Crude 
FREQUENCY(%) 
Ad). 	 Group 0 1-4 
RATES 
5-9 
PER MILLION 
10-14 	 crude Adj. Cun 
By(%) 
TOTAL 12 00 Si 66 209 100.0 100.0 100.0 05.1 151.3 91.0 119.3 118.5 119.3 1766 05.6 
I. 	 LSOKASMIAS 4 34 26 30 94. 46.9 47.2 100.0 28.4 74.7 46.4 54.2 55.6 56.0 1110 87.8 
Acute lymphocytic 2 29 22 20 73 34.9 ' 	 35.5 74,5 14.2 57.0 39.3 36.1 41.4 41.9 619 94.5 
Other lymphocytic 0 1 0 d 1 0.5 0.4 1.0 - 2.0 - 0.6 0.6 8 100.0 
Acute non-lymphocytic 1 5 2 0 16 7.7 7.4 16.3 7.1 9.8 3.6 14.5 9.1 8.9 137 $7.5 
Chronic myeloid 0 0 0 0 0 - - - - - - - - - 
Other and unspecified 1 3 2 2 a 3.0 3.6 8,2 7.1 5.9 3.6 3.6 4.5 4.6 67 25.0 
II. 	 1.108PsomAS 1 15 0 4 30 14.4 14.1 100.0 7.1 29.5 10.1 14.5 17.0 11.3 251 90.0 
Hodgkin's 	 di 	  0 5 2 6 11 6.2 6.1 43.3 - 9,8 3.6 10.8 7.4 7.3 111 100.0 
Non-Hodgkin lyaphoma 1 6 2 1 10 4.8 4.7 13.3 7.1 11.8 3.6 1.8 5.7 5.9 81 80.0 
Ourkitt's 	 lymphoma 0 0 1 0 1 0.5. 0.6 3,3 - - 1.0 - 0.6 0.6 9 100.0 
Unspecified lymphoma 0 1 1 0 2 1.0 1.0 6.7 2.0 1.8 - 1.1 1.2 17 100.0 
Mistiocyroais I 0 2 0 0 2 1.0 0.9 6.7 3.9 - 1.1 1.2 16 50.0 
Other reticuloendotholial 0 1 0 1 2 1.0 0,9 6.7 - 2.0 1.8 1.1 1.1 17 100.0 
III. MAIM AID SPIRAL 2 2 1 7 14 4.6 9.0 100.0 14.2 3.9 12.5 12.7 10.2 10.0 156 72.2 
Cpendymoma 0 0 0 0 0 - - - - -- - - - - 
katrocytoms 1 1 1 4 7 3.3 3.3 34.9 7.1 2.0 1.8 7.2 4.0 3.8 60 65.7 
Kedulloblastoma 0 0 0 1 1 0.5 0.5 5.6 - - 1.8 0.6 0.5 9 100.0 
Other glioaa 1 1 6 2 10 4.0 5.3 55.6 7.1 2.0 10.7 3.6 5.7 5.7' 87 60.0 
Other and unspecified • 0 0 0 0 0 - - - - - - - - - 
IV. 	 SINSATUSTIC M.S. 1 5 1 0 7 3.3 3.2 100.0 7.1 9.4 1.4 - 4.0 4.2 55 45.7 
Seuroblastoma 1 5 1 0 7 3.3 3.2 100.0 7.1 9.6 1.8 - 4.0 4.2 55 85.7 
Other 0 0 0 0 0 - - - - - - - - 
V. 	 RITIMOBLASTOMA 3 3 1 0 7 3.3 3.2 100.0 21.3 5.9 1.4 - 4.0 4.0 54 05.7 
VI. 	 KIDMIT 1 6 3 2 12 5.7 5.7 100.0 7.1 11.4 5.4 3.6 6.0 7.0 99 75.0 
Wilms* tumour 1 6 3 2 12 5.7 5.7 100.0 7.1 11.4 5.4 3.6 6.6 7,0 99 75.0 
Renal Carcinoma 0 0 0 0 0 - - - - - - - - 
Other and unspecified 0 0 0 0 0 - - - - - - 
VII. LI1,81 0 2 1 0 3 1.4 1.5 100.0 - 3.9 1.0 - 1.7 1.6 25 66.7 
Nepatoblastoma 0 2 0 0 2 1.0 0.9 66,7 3.9 1.1 1.2 16 100.0 
Hepatic carcinoma 0 0 1 0 1 0.5 0.6 33.3 - - 1.8 0.6 0.6 9 - 
Other nnd unspecified 0 0 0 0 0 - - - - - - - - 
TIZI.SORS 0 0 0 7 7 1.3 3.2 100.0 - - - 12.7 4.0 3.7 63 65.7 
Osteosarcoma 0 0 0 4 4 1.9 1.0 57.1 - 7.2 2.3 2.1 36 75.0 
Chondroaarcoma 0 0 0 0 0 - - - - 
- 
- 
- 
guing's sarcoma 0 0 0 3 3 1.4 1.4 42.9 - 5.4 1.7 1.6 27 100.0 
Other nnd unspecified 0 0 0 0 0 
- - 
- 
- 
- 
- 
- - 
II. 	 SOFT TISSOS SARCOMAS 0 7 3 1 11 5.3 5.3 100.0 - 13.0 5.4 1.0 6.2 6.5 91 01.8 
Ihabdomyosarcem* 0 6 1 1 8 3.8 3.7 72.7 11.6 1.8 1.8 4.5 4.8 65 100.0 
Fihrosarcoma 0 0 0 0 0 - - 
- 
- - - 
- 
- 
Other and unspecified 0 1 2 0 3 1.4 1.6 27.3 2.0 3.6 - 1.7 1.6 26 33.3 
I. 	 GoWAOAL 8 411RM Cita. 0 1 1 s a 3.4 3.4 100.0 2.0 1.8 10.8 4.5 4.3 71 67.5 
Von-gonadal germ cell 0 1 0 1 2 1.0 0.9 25.0 - 2.0 - 1.0 1.1 1.1 17 50.0 
Gonadal germ 0.11 0 0 1 5 6 2.9 2.9 75.0 - - 1.8 9.0 3.1 3.2 54 100.0 
Gonadal carcinoma 0 0 0 0 0 
- 
- - - - 
- - 
- - - 
other and unspecified 0 0 0 0 0 - - - - - - - 
II. 	 SPITMSLIAL Mi0FLASMS 0 1 2 5 a 3.0 3.9 100.0 2.0 3.6 9.0 4.5 4.4 71 100.0 
Adrenocortical carcinoma 0 0 D 1 1 0.5 0.5 12.5 - 1.8 0.6 0,5 9 100.0 
Thyroid carcinoma 0 1 0 4 5 2.4 2.3 62.5 - 2.0 - 7.2 2.8 2.7 14 100.0 
Maaopharyngeal carcinoma 0 0 0 0 0 - - - - - - - - 
Mel 	  0 0 1 0 1 0.5 0.6 12.5 - 1.0 - 0.6 3.6 9 100.0 
Other carcinoma 0 0 1 0 1 0.5 0.6 12.5 - - 1.8 0.6 0.6 9 100.0 
III. OTOS& 0 0 0 0 0 - - - - - - - - 
• Specified as malignant 0 0 0 0 0 
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for leukaemia being the highest by a considerable 
margin; this high rate is observed particularly for 
acute lymphocytic leukaemia. The rate for lym-
phoma was also high; for Hodgkin's disease, both 
the total frequency and the rates at younger ages 
were high. Rates for CNS tumours and neuro-
blastoma were low. The rate for nasopharyngeal  
carcinoma was high, though this was based on only 
seven cases, all in boys. 
Reference 
Salas, J. (1973) Lymphoreticular tumours in Costa Rica. J. nail 
Cancer Inst., 50, 1657-1661 
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arvical Cancer Risk and Use of 
Depot-Medroxyprogesterone Acetate 
in Costa Rica 
MARK W OBERLE•t. LU1S ROSERO-BIXBY", KATHLEENLIRWIPP, JUDITH A FORTNErt, NANCY C LEV, 
ANNE S WHATLEY* AND MICHELE G BONHOMMEt 
Oberle M W (Division of Reproductive Health. Centers for Disease Control, Atlanta GA 3033.1 USA), Rosero-Bixby 
L, Wan K L, Fortney .) A, Lee N C, Whatley A S, 8onhomme M G. Cervical cancer risk and use of depot-rneciroxy-
progesterone acetate in Costa Rica. international Journal of Epidemiology 1988. 17: 718-723. 
The relationship between cervical cancer and the use of depot-medroxyprogesterona acetate (OMPAI was 
examined in a nationwide case-control study in Costa Rica. Cases were women ages 25-58 years of age with 
invasive squamous cell cancer (N- 149) or carcinoma in situ (CIS, N =415) reported by the National Tumor Registry 
during 1982-84. Controls I N=764) were randomly selected during a nationwide household survey. Using logistic 
regression, we adjusted for known risk factors for cervical cancer OMPA use was associated with a risk of CIS of 
1.1 (95% confidence interval 0.6-1.8) and a risk of invasive cancer of 1.4 (95% confidence interval 0.6-3.1). The 
slightly elevated risks observed may be the result of chance or a detection bias. One limitation of this study is that 
few women had used DMPA for longer than two years. 
The long-term safety of the injectable contraceptive. 
depot-medroxyprogesterone acetate (DMPA). has 
been the subject of intense debate, chiefly because of 
reports of breast and endometrial neoplasia in animal 
studies. Most epidemiological studies of DMPA use 
and cancer have been hindered by small sample size 
and short periods of potential latency.' ' A recent. 
large case-control study by the World Health 
Organization (WHO) did not identify any overall 
increased risk of invasive cervical cancer among 
DMPA users." However, women who had used 
DMPA for five years or more had an elevated risk of 
invasive cervical cancer, compared to never users 
(odds ratio ---- 2.2. 95% confidence interval. 1.2 -4.2). 
This increased risk was confined to long-term users 
who were under 46 years of age at diagnosis or who 
began using DMPA before 30 years of age. The WHO 
study did not include cases of carcinoma in situ (CIS). 
Costa Rica offers an opportunity to examine the 
relationship between DMPA use and cervical cancer. 
because of its high incidence of cervical cancer and the 
popularity of DMPA after its introduction in the early 
1970s. In 1983. cervical cancer was the most 
• Do.i.tion 	 Reproduoire Hcaith. Centers for Dis<Ze.c Celnir01, 
GA 30333. USA 
•• 	 of Costa Rica , INISM. San I. 	 CoN1,1 Rica 
F.1f110 Heaith International. Research Mangle Park. NC 27709 
Present 3adrcsl Department of Epidemiology SC 36. School of 
Public Health and Cummunitr Medicine. 1:111‘ersil), of 
Seattle. Walhinttion 48195 USA 
commonly reported cancer and the second leading 
cause of cancer mortality among Costa Rican 
women.' The reported incidence of invasive cervical 
cancer in 1983 was 36.21100 000 women, one of the 
highest rates in the world.'s DMPA has been a popular 
contraceptive in Costa Rica: approximately 11 % of 
currently married women. 15-49 years of age have 
used an injectable contraceptive, chiefly DMPA.' 
However, since 1983. DMPA has not been approved 
for contraceptive use in Costa Rica. 
To further address the long-term safety of DMPA. 
the Costa Rican Demographic Association conducted 
a population-based. case-control study of cervical and 
breast cancer in Costa Rica in 1984-85. We report here 
our analysis of the association between DMPA use and 
cervical cancer. The breast cancer casts are the subject 
of a separate report.' 
CASES 
Since 1980. the Ministry of Health's National Tumor 
Registry has receiN,ed reports of cancer diagnosis from 
all major hospitals and pathologists in the country.'" 
Cases consisted of all women with invasive cervical 
cancer or CIS who were reported to the National 
Tumor Registry and had been diagnosed between 1 
January 1982. and 31 March 1984. Cases were 
restricted to women who were 25 -58 years of age at 
the time of diagnosis — the age groups likely to have 
used DMPA in Costa Rica. If the Tumor Registry did 
not have adequate information on the patient's address 
718 
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or her tumour's histological type. additional hospital 
records were reviewed. 
CONTROLS 
Controls consisted of a nationally representative. 
household sample of women age 25-59 years of age at 
the time of interview. The multistage area probability 
sample was based on a sampling frame from the June 
1984 national census. Sample points in sparsely settled 
areas and near the Nicaraguan border (representing 
5% of the population) were excluded. as were the 
cases from those areas. Although ail households had 
an equal probability of being selected, certain age 
groups were over-sampled so that the age distribution 
of the controls would match the age distribution of the 
combined group of all cancers in the study.' 
INTERVIEWS 
Cases and controls were interviewed itt their homes 
between September 1984 and February 1985. Trained 
female interviewers administered a standard question-
naire modified from the Cancer and Steroid Hormone 
Study.1° The questionnaire obtained information on 
reproductive and contraceptive history and other 
known or suspected risk factors for cervical cancer. 
Interviewers attempted to enhance recall by 
recording important life events and intervals of 
contraceptive use on a life history calendar. 
Of the 938 women eligible as controls. 93% were 
interviewed: 89% of the 583 carcinoma in situ (CIS) 
cases were interviewed (Table 1). However. only 66% 
of the 293 invasive cancer cases were interviewed, 
chiefly because 19% of these women had died before 
the interview period began. 
SEROLOGY 
At the time of interview a laboratory technician 
obtained a serum specimen from cervical cancer cases 
and controls, after informed consent was obtained. 
These sera were analysed blindly with respect to case 
control status for antibodies to three sexually 
transmitted diseases: Treponema pallidum, Herpes 
simplex type 2 (HSV-2). and Chlamvdia 
trachomaris.'"` 
EXCLUSIONS 
A panel of three Costa Rican gynaecological 
pathologists reviewed the interviewed cases' 
diagnostic cervical biopsy specimens. 
Cases were excluded if the initial diagnostic biopsy 
specimens could not be located, if a biopsy had not 
• been performed. or if the panel could not confirm the 
original histological diagnosis (Table 1). The panel  
also excluded cases with adenocarcinoma or adeno-
squamous histology because of possible differences in 
the epidemiology of these tumours.' Controls were 
excluded if they had a history of a cervical cone biopsy 
or hysterectomy. 
ANALYSIS 
Since interviews were conducted up to three years 
after the date of case diagnosis. and the exposure of 
interest occurred before diagnosis, we adjusted many 
variables to an index date. For each case. the index 
date was her date of diagnosis. For controls, we 
assigned an index date of 15 February 1983. the 
midpoint of the period of case eligibility_ Information 
on the questionnaire and calendar allowed us to adjust 
variables related to contraceptive use and reproductive 
histories to the index date. Women who were not 
25-58 years of age at this index date were excluded 
(Table 1). After all exclusions, the remaining study 
population consisted of 764 controls. 415 CIS cases. 
and 149 invasive cases. Serological specimens were 
available for 88.1% of the controls, 95.2% of the CIS 
cases, and 92% of the invasive cases. 
We used logistic regression models° containing 
'ever use' of DMPA and age at index date to screen for 
confounding effects by the following variables: 
socioeconomic status. education. geographical region. 
TABLE t Sutras of elier6.e cervical cancer cares and commis at 
ove•-•,e. and anahsa 
Interview status 
Eligible 4.0mt-ri 
Completed inter. law, 
Address unknown 
Deceased 
Absent 
Refused 
Other 
Total 
AnaI‘sis Status 
Completed 'mar, ,e- 
Included in analssis 
Excluded 
Slopsy not confirmed 
Non-squamous tspe 
Prior hssterectorni, 
Prior .one Mops!. 
Age at aides date 
CM or >58 
Other 
Total 
Women analysis 
720 
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marital status. gravidity, use of Papanicolaou smears. 
number of partners. number of spouses' prey lous 
marriages or consensual unions, age at first sexual 
intercourse, history of sexually transmitted disease or 
pelvic inflammatory disease, use of douching. tobacco 
use, oral contraceptive use, condom use and 
serological evidence of past infection with HSV-2. 
syphilis or chlarnydia. Only seven of these variables 
altered the risk estimate of cervical cancer and DMPA 
exposure minimally. and these seven were included in 
the final logistic regression analysis: age (continuous), 
gravidity {continuous), age at first sexual intercourse 
(continuous), history of sexually transmitted disease or 
pelvic inflammatory disease (ever, never), history of a
Papanicolaou smear before 1982 (ever, never), history 
of oral contraceptive use (ever, never), and number of 
sex partners (I, > 2). Women who had never had 
sexual intercourse 12 CIS cases and 47 controls) were 
excluded from the model. 
We characterized the relationship between cervical 
cancer and DMPA use by: ever use, total duration of 
use. time since first use, time since last use, and age 
at first use. We used the model described above to 
screen for interaction, that is, differences in cancer 
risk within subgroups of the following variables: 
education, socioeconomic status, age. region. 
gravidity, age at first sexual intercourse, number of 
sexual partners, STD history, and use of Papanicolaou  
smears, oral contraceptives, or tobacco. Additional 
details on study design and definitions have been 
published previously.' lb 
RESULTS 
On average. the CIS cases were younger than controls. 
while the invasive cases were older than controls-a 
consequence of the age-weighted control selection 
procedure (Table 2). Both case groups were more 
likely than controls to be of low socioeconomic status. 
to have become sexually active at a young age, to 
report a history of a sexually transmitted disease or 
pelvic inflammatory disease. and to report having 
three or more partners in their lifetime. 
Ever users of DMPA had a risk of CIS of 1.1 when 
compared with never users t 95 % CI = 0.6 - 1.8. 
Table 3). There was no clear pattern of CIS risk by 
duration or time since first or last use of DMPA. 
Women who first used DMPA before age 30 had a CIS 
risk of 0.6 (95% CI = 0.3 -1.7) whereas users who 
began use after age 39 had a risk of 2.0 (95% CI = 
0.8 -5.5). Both of these risk estimates were based on 
small numbers of users. However, when we analysed 
in more detail the subgroup of women who began 
7.11t.F 2 	 Per cent distribution of vases and enntrnis by selected 
charactenslics 
CIS 
cases 
characteristic 
	 iN*4151 
Inv.tvive 
cases 
iN=149) 
Controls 
064i 
lge at index date 
23-29 
 22.2 7 4 19 0 
30-34 29.4 :0 1 20.3 
35-39 21.9 12 8 16.1 
40-44 14.2 16.1 13.9 
45 -49 7.2 13.4 13 9 
50-54 3.1 14_1 11.3 
55-58 1.9 16.1 5.6 
Region 
Metropolitan San lose 33.3 35.0 32.2 
Non-metro Central valley 34.5 23.5 33.1 
Outside Central Valley 32.2 44.3 31.9 
Socioeconomic status 
Low 52.1 66.4 45.7 
Medium 28.7 20.1 28.8 
High 
cu Age 	 first coitus 
 
19.3 13.4 25.5 
<16 
None 
2
0.2
4.6 
0.0 
28.2 
5.6 
13.9 
16-17 22.2 28.2 19 2 
18-19 21.9 23.5 17 2 
20-21 14.0 9.4 13.7 
2_ 22 16.9 10.1 29.8 
Unknown 0.2 0,7 0.5 
Noodle, of lifetime se.tii..ii partners 
None 0 2 0.0 5.6 
1 48.7 41.6 64.7 
2 24.6 26.2 16.5 
3 11,8 10.7 8.0 
4 13.7 19.5 4.5 
Unknown 1.0 2.0 0.8 
Number of pregnancies 
0 1 7 1.3 8.8 
1 8.4 
 
'7 2 3 4 
2 15.2 6 7 13.5 
3 19 3 6.0 17 0 
4 14 5 10 
	
1 12.7 
z_ 5 41 9 72.5 39 5 
Unknown 0.2 0.0 0 1 
Number of Pap smears before 1982 
0 
1-9 60.1 
 
9 9 
61 7 
40.3 
45 0 
25.9 
.2.. 10 27.7 12.13 13 	 1 
Unknown 
firstory of seruall% trcutsrrutted 
diseale iSTD) 
0 7 2.0 0 8 
Yes 32_3 26.8 9 2 
No 64 8 72.5 90 0 
Unknown 2.9 0 7 0.8 
STD serolog% 
Reactive for syphills 9 I 17 5 6.5 
Poviiive for RSV.: 41 5 
 
57 5 62.8 
Povitive for chlamsdia. 68 9 73 0 57 3 
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using DMPA after age 39. the increased risk was 
confined to women who had used DMPA during the 
year prior to their index date. For women who first 
began using DMPA after agc 39 and who were using 
DMPA during the year prior to their index date. the 
risk of CIS was 4.5 (95% CI = 1.0-19.7. data not in 
table). 
Ever users of DMPA had a risk of invasive cancer 
of 1.4 when compared with never users i95% CI = 
0.6-3.1. Table 4). However. all estimates for 
invasive cancer were based on only 10 cases who 
reported use of DMPA. The point estimates of 
invasive cancer risk were slightly higher for women 
with less than a year of use and for women with more 
recent use. There was no change in risk with varying 
age at, or time since, first use of DMPA. 
Controls who reported a history of DMPA use were 
more likely to have had a Papanicolaou smear before 
1982 than controls who had never used DMPA (89% 
versus 74%. Table 5). This appeared to be true in each 
age. geographical, and socioeconomic subgroup. 
although there were few DMPA users in most strata. 
TABLE 3 Risk of carcinoma in situ 11 relation ro IIMP.4 use by 
duration. tune suice first use. rime since la!: use and age or first use 
Number of 
cases. 
controls 
Adjusted 
OR• 
95% 
Confidence 
intervals 
Ever uset 
Never 341 606 I 0 !referent, 
Ever :8.40 1 	 I 0 6-1 8 
Duration of use* 
<1 year 16, 22 1.1 0.6-2.2 
year 7 , 6 1.4 0.4-4 6 
2._ 2 years 
since first mu,* 
4.10 1 0 0.3-3 2 
<5 Years 16 19 1 	 3 0 6-2 6 
5-9 years 6.11 08 0.3-2 4 
2. 10 years 58 1 2 0 4-3 9 
Time since lass use* 
<1 year 9, 13 12 0.5-30 
1-4 yearS 10112 1 	 2 0.5-3 1 
2 5 years 8/13 10 0 4-2 4 
Age at first use* 
<30 years 7 14 0 6 03-1 
30-39 years 1114 1 	 2 0 5-2 8 
2_ 40 years 10 2 0 U 8 -5 5 
• Odds ratio adjusted for agc at index dale. histors of sexually 
transmitted disease or pelvic inflammatory disease, gra. laity. age at 
first sexual relationsnip, number ut partners. use 01 oral 
contraceptives. and history of Pspanicolaou smears berme 1982 
f Excludes 46 cases and 118 controls with unknown sallies for 
DMPA use or confounding variables 
1 case and 2 controls excluded (Or incomplete intormanon sn dates 
of DMPA use, in addition to abase exclusions 
DISCUSSION 
Users of DMPA in Costa Rica had a slightly elevated 
risk of invasive cervical cancer (OR =1.4), but the 
confidence interval included 1.0. The small number of 
cases and the lack of a biologically plausible effect of 
duration and time since first use suggest that this 
elevated risk could have been due to chance. These 
findings are consistent with the WHO study's risk 
estimate of 1.2 for invasive cancer (95% CI 
0.9-1.8). An elevated risk of invasive cancer in the 
WHO study was restricted to a subgroup of women 
who had used DMPA for five years or conger.` We 
could not examine this group in detail in our study. 
since only three controls and no invasive case had used 
DMPA for longer than five years. In addition to the 
limited number of long-term users, the small number 
of cases in most strata limited our analysis (Table 4). 
Ever use of DMPA was associated with an odds 
ratio for CIS of 1.1 One subgroup of cases appeared 
to have an elevated risk—women who began use after 
age 39 (OR =2.0. 95% C1=0.8-5.5). However, 
chance may explain the risk estimate for this 
subgroup. since the confidence interval included 1.0. 
Detection bias might explain the elevated risk in this 
and other subgroups in this study because of 
TABLE 4 Risk nf otrassie cervical cancer in relation to DMPA use 
b:t duration. rime Imre, first use, rime since last use, and age at firs: 
use 
Number of 
cases/ 
controls 
95% 
Adjusted Confidence 
OR• 	 intervals 
Es er wet 
Never 123606 1.0 treferersil 
Ever 10,40 1 4 116-3.1 
Duration of use* 
<I year 7, 22 I 	 7 0.6-4.7 
2 1 year 116 12 0.3-4.5 
Time since first use* 
<5 years 5.19 1.5 0.5-4.5 
2_ 5 years 5.19 15 0.5-4.6 
Time srnce lass 1.43r* 
<5 years 7 25 16 0 6-4 3 
2_ 5 years 3 , 13 I 	 2 0.3-5 0 
4eft as first irlr* 
<35 years 523 I 	 5 0 5 - 4 5 
35 years 5. I 5 1 	 5 0 4-4 5 
• Odds ratio adjusted for age .0 index date, history of sexually 
transmitted disease or pelstc inflammatory disease. gravidity. age at 
first sexual relationship. number of partners, use of oral 
contraceptives. and history of Papanicolaou smears before 1982. 
Referent group conststs sit those who bad neser used DMPA 
j' Excludes 16 cases and 118 ,..ontrois with unknown salves for 
DMPA use or confounding sariabies 
*2 additional controls excluded for incomplete information tin dates 
of DMPA use. in addition to abase exclusions 
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differential surveillance for disease between ever users 
of DMPA and never users. To identify the possibility 
of detection bias. we compared the percentage of 
women reporting a history of a Pap smear among 
controls who had ever used DMPA and controls who 
have never used DMPA. Since the controls are a 
representative sample of Costa Rican women, their use 
of Pap smears before the case eligibility period began 
reflects the extent to which DMPA use and cervical 
cancer screening are associated in the general 
population. If DMPA users are more likely to obtain 
a Pap smear than are non-users, then DMPA users 
with CIS would be more likely to be detected than 
women with CIS who did not use DMPA. Conse-
quently. DMPA users would be overrepresented 
among the CIS cases, resulting in spuriously elevated 
risk estimates. This may explain the observed slight 
elevations of risk estimates. especially for CIS. which 
is usually identified only through Pap screening. A 
comparable analysis for oral contraceptives from this 
study suggested that detection bias might explain the 
positive association between oral contraceptive use 
and CIS in Costa Rica.'6 In contrast, screening for 
breast cancer is not associated with DMPA use in 
Costa Rica," 
Detection bias may have contributed to the elevated 
risk estimate for CIS among the subgroup of users who 
first used DMPA after age 39. but there were too few 
DMPA users in this age group to adequately assess the 
possibility of differential surveillance by age. 
However, the observation that the increased risk in 
this subgroup was restricted to recent users is 
TABLE S Controls reporting at leas: one Papas...cobras, smear 
before 1982 by eler use of DMPA ult.! 	 seieurea character's:4,1 
CharacteristIc 
DMPA ever user 
% %van Pap' 
DMPA never 
Liver 
et won Pap' 
All ,onirois 89 3 74 2 
4ge u, indrr date 
'5-34 90 3 '7 
57 0 76 6 
90 tri 4 
RereLlente 
Metro fan Jose 91 1 13 	 11  
Non•metru Central Valley 100 0 '1 S 
Outside Central Valley 82 	 1 65 is) 
,,etonsiroo 	 swots 
1-0% 88 65 3 
Medium 53 4 1 
High 100 0 db 
Number of women 351 17191 
• Adjusted to the age distrIbution of the general prnsulation of Costa 
Rena 
consistent with a detection bias, since recent users are 
likely to be recently screened for cervical pathology in 
conjunction with their clinic visits. 
We attempted to minimize recall bias by the use of 
a life history calendar as a memory aid. Since other 
injectable contraceptives were used rarely by private 
physicians over the last decade. it is possible that some 
women could have confused a one-month injectable 
contraceptive for the three-month injectable. DMPA. 
However. including users of any injectable contracep-
tive with DMPA users did not alter the risk estimates. 
Interviewer training and a standard questionnaire for 
both cases and controls should have reduced the 
likelihood of an interviewer bias. However, it was not 
possible to keep interviewers unaware of case-control 
status. 
Ascertainment bias should have been minimal since 
all hospital and pathologists in the country participate 
in the National Tumor Registry. In one review of 
hospital discharges. the registry detected 98% of 
women 
	 hospitalized 	 for 	 gynaecological 
malignancies.° In addition, the validity of the 
diagnosis in this study was enhanced by including only 
cases whose histological classification had been 
confirmed by a panel of gynaecological pathologists. 
The exclusion of cases who did not have a diagnostic 
biopsy confirmed by the pathology panel probably did 
not bias the risk estimates, because, in additional 
analyses that included these patients, risk estimates for 
DMPA use in association with CIS or invasive cancer 
did not change appreciably. 
Although we examined the possibility of 
confounding by most of the established risk factors for 
cervical cancer, we could not examine two probable 
risk factors. We did not interview the male sex 
partners of the cases and controls about their sexual 
histories. However, the three STD serological tests 
may have served as a partial surrogate for the possible 
effects of the partners' sexual disease history.° We 
also could not examine exposure to human 
papillomavirus as a potential confounder, since no 
type-specific serological rest is available for this group 
of 	 'Viruses.'" 
	 Circumcision 	 and 	 use 	 of 
diethylsolboesterol 4DES) have never been common in 
Costa Rica. so these topics were not included in the 
questionnaire. 
The lack of a clear association between DMPA use 
and cervical cancer in this case-control study and in 
the WHO study' is reassuring, since the study designs 
differed. The Costa Rica study had a national. 
population-based design whereas WHO's was a 
multicentre. hospital-based design. However, the 
elesated risk of in+asive cancer suggested by the 
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WHO study for long-term DMPA users who began 
DMPA use at an early age could not be confirmed in 
Costa Rica because of the rarity of long-term use. 
Although statistical chance in the WHO study may 
account for the elevated risk in this subgroup, 
additional investigation appears warranted. Since only 
14 years had elapsed between DMPA's introduction 
into Costa Rica and this study's eligibility period. we 
would not have been able to detect cancers resulting 
from a longer latency effect. In addition, future studies 
of the relationship between cervical cancer and 
hormonal contraceptives should investigate the 
possibility of detection biases that may explain 
observed associations. 
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